Status:
COMPLETED
Anxiety Sensitivity Program for Smoking Cessation
Lead Sponsor:
University of Vermont
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this study is to develop and test a smoking cessation intervention for persons who are specifically sensitive to anxiety and anxiety-related bodily sensations.
Eligibility Criteria
Inclusion
- Aged between 18 and 65 years old
- Not pregnant
- Regular smoker averaging 10 or more cigarettes per day for at least one year
- Score of 25 or greater on 16-item Anxiety Sensitivity Index
- Motivation to Quit score of 7 or greater (using Readiness to Quit Ladder)
- Not currently using pharmacotherapy for smoking cessation (e.g., Zyban)
- No use of other tobacco products (e.g., chewing tobacco, cigars)
- No Axis-I or Axis-II diagnoses other than mood or anxiety disorders (intake interview required)
- No suicidal or homicidal ideation
- No current psychotropic medication use
- No evidence of substance abuse or dependence (other than nicotine dependence)
- No history of significant medical conditions (cardiovascular, neurological, etc.)
- Ability to provide informed, written consent (no evidence of limited mental capacity)
- Sufficient command of the English language (able to carry on interview conversation)
- Plan to stay in Burlington VT area for at least next 6 months
Exclusion
- Not between 18-65 years old
- Pregnant or currently trying to become pregnant
- Regular smoker for less than one year OR smoke less than 10 cigarettes per day
- ASI below cutoff level of 25
- Motivation to Quit score of 6 or less (using Readiness to Quit Ladder)
- Current or recent use of any pharmacotherapy for smoking cessation (e.g., patch, Zyban)
- Current use of other tobacco products (e.g., chewing tobacco, cigars)
- Axis-I disorders other than anxiety or mood disorders.
- Endorsement of suicidality or homicidal ideation.
- Any current psychotropic medication use (must have stopped at least 1 month prior).
- Any evidence of substance abuse or dependence (other than nicotine dependence)
- Any history of significant medical conditions (cardiovascular, neurological, etc.)
- Inability to provide informed, written consent (evidence of limited mental capacity)
- Insufficient command of the English language (unable to carry on conversation)
- Plan to permanently leave Burlington area anytime during the next 6-12 months
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2010
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00387049
Start Date
January 1 2005
End Date
April 1 2010
Last Update
October 22 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vermont
Burlington, Vermont, United States, 05405